Enhancing T-cell response with monoclonal antibodies and chemotherapy in advanced gastric cancer

doi:10.4251/wjgo.v17.i7.104806

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 7

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (0)

All Articles published online

The chart showing PDF series, HTML series, Tables (1-1) series.

Item

Count

PDF

HTML

Tables (1-1)

Sum=0

Jul 15, 2025 (publication date) through Jul 14, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Letter to the Editor

World J Gastrointest Oncol. Jul 15, 2025; 17(7): 104806
Published online Jul 15, 2025. doi: 10.4251/wjgo.v17.i7.104806

Enhancing T-cell response with monoclonal antibodies and chemotherapy in advanced gastric cancer

Ana Carolina Pires, Pedro Luiz Serrano Uson Junior

Ana Carolina Pires, Department of Oncology, Oncoclínicas, Rio de Janeiro 22250905, Brazil

Ana Carolina Pires, Hospital Universitário Gaffrée e Guinle, Rio de Janeiro 22250905, Brazil

Pedro Luiz Serrano Uson Junior, Center for Personalized Medicine, Hospital Israelita Albert Einstein, São Paulo 05652900, Brazil

Pedro Luiz Serrano Uson Junior, Department of Oncology, Hospital do Coração (HCOR), Sao Paulo 04004030, Brazil

Author contributions: Pires AC and Uson Junior PLS wrote the article, reviewed and approved the final manuscript.

Conflict-of-interest statement: There is no conflict of interest associated with the senior author and other co-authors regarding their contributions to this manuscript.

Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Pedro Luiz Serrano Uson Junior, MD, Assistant Professor, Center for Personalized Medicine, Hospital Israelita Albert Einstein, Avenida Albert Einstein 627, São Paulo 05652900, Brazil. pedro.serrano@einstein.br

Received: January 7, 2025
Revised: January 23, 2025
Accepted: February 10, 2025
Published online: July 15, 2025
Processing time: 193 Days and 10.4 Hours

Core Tip

Core Tip: After six cycles of treatment with chemotherapy and trastuzumab it was observed that the levels of tumor markers in the blood significantly dropped compared to their initial values. Furthermore, there was a notable increase in the percentages of CD3+ and CD4+ T cells, with the CD4+/CD8+ ratio also increasing after treatment. Patients who had a reduction of 50% or more in their tumor markers and an increase in the CD4+/CD8+ ratio showed better disease outcomes. These findings can be related to the current field of advancements in the treatment of human epidermal growth factor receptor 2 positive gastric cancer, with the combination of immune checkpoint inhibitors.